Xoma completes enrollment in diabetes trial
Добавлено: 30.09.2010, 15:35
Xoma Ltd. completed enrollment in a mid-stage trial of its potential once-a-month diabetes treatment.
The Berkeley-based company (NASDAQ: XOMA) said 74 patients with Type 2 diabetes were enrolled in the Phase IIa trial of XOMA-052, a monoclonal antibody. that inhibits the inflammatory cytokine interleukin-1 beta.
Xoma said it expects to report early data from the six-month study in January 2011.
Xoma also is continuing a 420-patient Phase IIb trial of XOMA-052 and expects to report that data in first-quarter 2011.
Read more: Xoma completes enrollment in diabetes trial - San Francisco Business Times
The Berkeley-based company (NASDAQ: XOMA) said 74 patients with Type 2 diabetes were enrolled in the Phase IIa trial of XOMA-052, a monoclonal antibody. that inhibits the inflammatory cytokine interleukin-1 beta.
Xoma said it expects to report early data from the six-month study in January 2011.
Xoma also is continuing a 420-patient Phase IIb trial of XOMA-052 and expects to report that data in first-quarter 2011.
Read more: Xoma completes enrollment in diabetes trial - San Francisco Business Times